Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

Dispatches from PCT US

Experts discuss the impact of M&A on CRO, sponsor partnerships

As M&A continues to ramp up for the pharma and biotech industry, communication and agility are two of the major keys for CROs to adapt to an acquisition, experts said Thursday at the Partnerships in Clinical Trials Conference in Boston.

M&A impact mulled at PCT
Dispatches from PCT US

TransCelerate CEO, leaders offer update on industry group’s activities

As 20 of the largest biopharma companies have now joined industry group TransCelerate, the group is beginning to use patient centricity and connectivity to influence the clinical trial environment, CEO Dalvir Gill told attendees at the Partnerships in Clinical Trials Conference on Friday in Boston.

Bio-CMO sector to grow over 40% on Big Biopharma's burgeoning pipelines

Cheaper disposable manufacturing techs and increased demand for outsourced production will see more CMOs enter the contracting sector according to HighTech Business Decisions

Thermo Fisher to offer clients Horizon's X-MAN cell line tech

Thermo Fisher has added X-MAN cell line services to its biopharma R&D offerings through a supply agreement with Horizon Discovery Group.

Dispatches from PCT US

All about that base: Risk-based monitoring takes center stage

As sponsors and CROs continue the inevitable shift away from 100% SDV (source data verification) in line with US FDA and TransCelerate guidance, new risk-based monitoring (RBM) strategies are cropping up in various ways across the industry.

Pfizer reveals PPD as third strategic CRO partner

Pfizer has selected PPD as its third preferred contract research organisation (CRO), but the addition will not affect ongoing relationships with Parexel and Icon, the firm says.

Merck 'bio-inks' deal to use Organovo's 3D printed liver for preclinical studies

Merck & Co. has struck a deal with Organovo to use a 3D printed human liver system for toxicology testing as a supplement to in vitro and preclinical animal testing.

MHRA licence to allow CDMO Juniper to manufacture 'Specials'

Juniper has received a licence to make unlicensed medicinal products but will only produce batches with relatively high volumes to keep clients’ costs down.

Key Industry Events